



5 November 2024

genedrive plc
(“genedrive” or the “Company”)

Genedrive featured in UK Government Department for Business and Trade spotlight on UK genomics

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that it has been featured in the UK Government Department for Business and Trade (“DBT”) publication *“UK Genomics Spotlight 2024: Celebrating success and looking ahead”*

The document is available at <https://eu.eventscloud.com/website/6238/life-sciences/>. The report highlights the UK’s depth and breadth of expertise for export as world leaders in the field of genomics, as well as opportunities for investing in the UK. It describes the ecosystem which has enabled the delivery of genomic medicine in the UK and expertise in various national initiatives and programmes which are contributing to the genomics landscape of the future.

The DBT has produced the Genomics Spotlight 2024 to showcase the UK’s expertise in genomics and latest developments that make the UK a hub for genomics business and investment, and has worked closely with the NHS, including NHS England and all three of the devolved nations, as well as encouraging input from several key organisations and companies in the UK.

The document showcases UK capabilities in genomics, with the aim to promote this sector to markets around the world, to promote UK plc and the healthcare institutions in place. It highlights both the export potential of UK companies, as well as the investment potential across the wider NHS infrastructure and research institutes, being a reminder of the world leading genomics capabilities of the UK, from the NHS Genomic Medicine Service, to world leading institutions and research cohorts, and the ever-expanding innovation of UK small businesses.

Gino Miele, CEO of genedrive plc, said: *“We are delighted to be featured in this spotlight document from the UK Department for Business and Trade on UK genomics capabilities. Genedrive are at the forefront of enabling near-patient pharmacogenetic testing in emergency care paradigms and recognition in features such as this ultimately facilitate education, awareness and promotion of our innovative products in both domestic and international markets.”*

For further details please contact:

genedrive plc +44 (0)161 989 0245

Gino Miele: CEO / Russ Shaw: CFO

Peel Hunt LLP (Nominated Adviser and Broker) +44 (0)20 7418 8900

James Steel / Patrick Birkholm

Walbrook PR Ltd (Media & Investor Relations) +44 (0)20 7933 8780 or genedrive@walbrookpr.com

Anna Dunphy

+44 (0)7876 741 001

About genedrive plc (<http://www.genedriveplc.com>). genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront

of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.